Sinotherapeutics Inc. (688247.SH) plans to launch a restricted stock incentive plan for 2025.

20:01 25/12/2025

Xuantai Pharmaceuticals (688247.SH) announced its 2025 Restricted Stock Incentive Plan (Draft), planning to grant up to 6.23 million shares to incentive recipients, accounting for approximately 1.37% of the total share capital of the company at the time of the announcement of the incentive plan draft. Of these, up to 4.988 million shares will be granted for the first time, to not more than 64 incentive recipients, at a grant price of 5.71 yuan per share.

Sinotherapeutics Inc. (688247.SH) has announced its 2025 Restricted Stock Incentive Plan (draft), intending to grant a maximum of 6.23 million shares to incentive recipients, accounting for approximately 1.37% of the total share capital of the company at the time of the draft announcement. Among them, the initial grant will not exceed 4.988 million shares, with a maximum of 64 recipients for the initial grant, at a grant price of 5.71 yuan per share.

Harbin Boshi Automation (002698.SZ) shareholder Cai Zhihong plans to reduce his shareholding by no more than 2.9338%.

Hubei Wanrun New Energy Technology (688275.SH) partially reduced production line for maintenance, with an expected decrease in lithium iron phosphate production by 5,000 to 20,000 tons.

Shenzhen Cotran New Material (300731.SZ)proposes to launch a restricted stock incentive plan for 2025.

Harbin Boshi Automation (002698.SZ) shareholder Cai Zhihong plans to reduce his shareholding by no more than 2.9338%.

Hubei Wanrun New Energy Technology (688275.SH) partially reduced production line for maintenance, with an expected decrease in lithium iron phosphate production by 5,000 to 20,000 tons.

Shenzhen Cotran New Material (300731.SZ)proposes to launch a restricted stock incentive plan for 2025.